Who is sponsoring NCT05858515?

NCT05858515 is sponsored by Vanderbilt University Medical Center.

What drugs are being tested in NCT05858515?

Interventions in NCT05858515: Baricitinib 4 MG, Placebo.

What condition does NCT05858515 study?

NCT05858515 studies Post-Acute COVID-19 Syndrome.

Is NCT05858515 still recruiting?

NCT05858515 is currently withdrawn. Last updated 31 January 2025.

Last reviewed 2025-01-31 · How we verify

NCT05858515: REVERSE-LC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

REVERSE-Long COVID-19 With Baricitinib Study

Withdrawn Phase 3 Last updated 31 January 2025

What this trial tests

Phase 3 trial testing Baricitinib 4 MG in Post-Acute COVID-19 Syndrome. Withdrawn.

Timeline

21 October 2024

Primary endpoint
31 December 2027

30 December 2029

Quick facts

Lead sponsor	Vanderbilt University Medical Center
Phase	Phase 3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Start date	21 October 2024
Primary completion	31 December 2027
Estimated completion	30 December 2029
Sites	6 locations across United States

Drugs / interventions tested

Baricitinib 4 MG — full drug profile →
Placebo

Conditions studied

Post-Acute COVID-19 Syndrome — all drugs for Post-Acute COVID-19 Syndrome →

Sponsor

Vanderbilt University Medical Center

Who can join

18 and older, any sex, with Post-Acute COVID-19 Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

REVERSE-LC is a phase 3 trial of baricitinib versus placebo in adults with neurocognitive impairment (a form of Alzheimer's Disease and Related Dementias or ADRD) or cardiopulmonary symptoms due to Long COVID.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Fighting Post-COVID and ME/CFS - development of curative therapies.
Scheibenbogen C, Bellmann-Strobl JT, Heindrich C, Wittke K, et al · · 2023 · cited 32× · PMID 37396922 · DOI 10.3389/fmed.2023.1194754
Infection-associated chronic conditions: Why Long Covid is our best chance to untangle Osler's web.
Peluso MJ, Hanson MR, Deeks SG. · · 2024 · cited 9× · PMID 39536121 · DOI 10.1126/scitranslmed.ado2101
Post-COVID-19 condition, brain fog, and fatigue-what do we know now?
eBioMedicine. · · 2024 · cited 2× · PMID 38997174 · DOI 10.1016/j.ebiom.2024.105252

Verify or expand the search:

Other trials of Baricitinib 4 MG

Trials testing the same drug.

NCT06439615 — Baricitinib for the Lung Injury Following Spontaneous SAH · Phase 2 · not yet recruiting
NCT06065046 — Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions · Phase 2 · recruiting
NCT05969730 — Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis · NA · completed
NCT05914584 — "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype. · Phase 2, PHASE3 · unknown
NCT06662721 — Baricitinib for Refractory Takayasu Arteritis · Phase 2 · completed

Other Vanderbilt University Medical Center trials

Trials by the same sponsor.

NCT07005037 — Swallowing Impairments in ICU Survivors and Community-Dwelling Adults · not yet recruiting
NCT07527273 — Cognitive Enhancement in Recurrent Depression (The COG-D-R Study) · NA · not yet recruiting
NCT07295288 — Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis · Phase 4 · not yet recruiting
NCT07431541 — Topical Carboxytherapy Paste Following Microneedling · Phase 1, PHASE2 · not yet recruiting
NCT07224711 — The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05858515 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt University Medical Center
Last refreshed: 31 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05858515.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing